![](https://investorshub.advfn.com/uicon/81806.png?cb=1635633872)
Friday, June 20, 2008 12:07:08 PM
Friday June 20, 11:04 am ET
Trubion says Wyeth extends research deal on drug candidate for arthritis, cancer
SEATTLE (AP) -- Biopharmaceutical company Trubion Pharmaceuticals Inc. said Thursday Wyeth the companies' research partnership for an additional year, resulting in $3.2 million of additional funding from Wyeth.
Trubion shares rose 41 cents, or nearly 8 percent, to $5.69, while Wyeth shares shed 8 cents to $47.74 in morning trading.
The extension continues through Dec. 29, 2009 a collaboration on TRU-015, currently in mid-stage development for rheumatoid arthritis, and other candidates that target the protein CD20 found in B cells in the immune system.
TRU-015 is also in early-stage development for B-cell cancers such as non-Hodgkin's lymphoma and leukemia and is in pre-clinical development as a treatment for lupus.
Under an agreement signed in December 2005, Trubion received a $40 million upfront payment, and is eligible for development milestones and royalties up to $800 million.
![](http://www.creativeoneart.com/art2005/girl_on_beach.jpg)
surf's up......crikey
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM
Maybacks Adds Award Winning Show to Its Lineup Discusses Maybacks Opportunity • AHRO • Aug 22, 2024 11:30 AM
North Bay Resources Announces First Gold Concentrate at Mt. Vernon Gold Mine, Assays 12 oz/ton Gold, 17.5 oz/ton Platinum, and 8 oz./ton Silver, Sierra County, California • NBRI • Aug 22, 2024 10:28 AM
All Things Mobile Analytic, Inc. Reports Major Growth with Over $11 Million in Revenue • ATMH • Aug 22, 2024 7:19 AM
Unitronix Announces Strategic Entry into Cryptocurrency Space • UTRX • Aug 21, 2024 10:00 AM